Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib

Nature Clinical Practice Oncology volume 3, pages 602–603 (2006)Cite this article

boxed-textRatain MJ et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505–2512

Sorafenib is reasonably well tolerated and could delay disease progression in cytokine-refractory, metastatic RCC, but further study is required

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rini BI and Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028–1043

    Article  CAS  Google Scholar 

  2. Escudier B et al. (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract #4510]. J Clin Oncol 23 (Suppl)

  3. Bukowski RM et al. (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma [abstract #4523]. J Clin Oncol 24 (Suppl)

  4. Motzer RJ et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516–2524

    Article  CAS  Google Scholar 

  5. Hudes G et al. (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) [abstract #LBA4]. J Clin Oncol 24 (Suppl)

Download references

Acknowledgements

The synopsis was written by Carol Lovegrove, Freelance Medical Writer.

Author information

Authors and Affiliations

  1. staff member in the Department of Solid Tumor Oncology at the Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    Brian I Rini

Authors
  1. Brian I Rini
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has received research support and is an advisor to Bayer and Onyx Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rini, B. Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. Nat Rev Clin Oncol 3, 602–603 (2006). https://doi.org/10.1038/ncponc0634

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0634

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing